Skip to main content
HO

Hemoglobin Oxygen Therapeutics

Hemoglobin Oxygen Therapeutics develops hemoglobin-based oxygen carriers as blood substitutes to improve oxygen delivery in medical settings. Their technology aims to provide a stable, transfusion‑compatible solution for patients requiring enhanced oxygen transport, such as during surgery or trauma care.

Souderton, PennsylvaniaFounded 20147100+ followers
Updated 1 month ago

Funding

$150K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Patients with severe hypoxia or compromised tissue oxygen delivery often experience limited treatment options, leading to prolonged ICU stays, organ dysfunction, and higher mortality. Conventional oxygen therapies provide only transient increases in blood oxygen levels without directly enhancing oxygen transport to affected tissues.

Solution

Hemoglobin Oxygen Therapeutics creates engineered hemoglobin-based oxygen carriers that can be administered intravenously to augment systemic oxygen delivery. These formulations are designed to release oxygen in a controlled manner, matching tissue metabolic demand and improving cellular respiration. By acting as a supplemental oxygen transport system, the products aim to stabilize patients in critical care settings and support chronic disease management where oxygen deficiency is a key factor. The technology is being developed for integration into existing hospital protocols, offering clinicians an additional therapeutic option to address refractory hypoxemia.

Target Audience

Primary customers are hospitals, intensive care units, and specialty clinics treating patients with acute respiratory failure, severe anemia, or chronic conditions characterized by impaired tissue oxygenation.

Features

  • Recombinant or chemically modified hemoglobin molecules optimized for stability and reduced immunogenicity
  • Controlled oxygen release kinetics tailored to physiological tissue oxygen consumption rates
  • Compatibility with standard intravenous infusion equipment and hospital supply chains
  • Scalable manufacturing process enabling consistent product quality and batch-to-batch reproducibility
  • Formulations designed for use alongside conventional ventilatory support and oxygen therapy
This profile is AI-generated and may contain inaccuracies.